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Abstract
Background: Ceruloplasmin, a ferroxidase present in cerebrospinal fluid (CSF), plays a role in iron homeostasis
protecting tissues from oxidative damage. Its reduced enzymatic activity was reported in Parkinson’s disease (PD)
contributing to the pathological iron accumulation. We previously showed that ceruloplasmin is modified by oxidation
in vivo, and, in addition, in vitro by deamidation of specific NGR-motifs that foster the gain of integrin-binding function.
Here we investigated whether the loss of ceruloplasmin ferroxidase activity in the CSF of PD patients was accompanied
by NGR-motifs deamidation and gain of function.
Results: We have found that endogenous ceruloplasmin in the CSF of PD patients showed structural changes,
deamidation of the 962NGR-motif which is usually hidden within the ceruloplasmin structure, and the gain of
integrin-binding function. These effects occur owing to the presence of abnormal levels of hydrogen peroxide
we detected in the CSF of PD patients. Interestingly, the pathological CSF's environment of PD patients
promoted the same modifications in the exogenously added ceruloplasmin, which in turn resulted in loss of
ferroxidase-activity and acquisition of integrin-binding properties.
Conclusions: We show that in pathological oxidative environment of PD-CSF the endogenous ceruloplasmin,
in addition to loss-of-ferroxidase function, is modified as to gain integrin-binding function. These findings,
beside the known role of ceruloplasmin in iron homeostasis, might have important pathogenic implications
due to the potential triggering of signals mediated by the unusual integrin binding in cells of central nervous
system. Furthermore, there are pharmacological implications because, based on data obtained in murine models, the
administration of ceruloplasmin has been proposed as potential therapeutic treatment of PD, however, the observed
CSF's pro-oxidant properties raise the possibility that in human the ceruloplasmin-based therapeutic approach might
not be efficacious.
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Background
Ceruloplasmin (Cp) is a ferroxidase enzyme expressed on
the surface of astrocytes and secreted as a soluble form in
the cerebrospinal fluid (CSF) by choroid plexus epithelial
cells [1]. Ceruloplasmin plays an important role in cellular
iron homeostasis and protects tissues from oxidative dam-
age [2, 3]. Significant loss of ceruloplasmin-ferroxidase
activity has been observed in CSF and substantia nigra of
patients with Parkinson's disease (PD), suggesting a role of
ceruloplasmin dysfunction in neurodegenerative diseases
characterized by oxidative stress [3–7]. Consistently,
ceruloplasmin-KO mice and patients with genetic acerulo-
plasminemia have increased iron accumulation in brain,
neurodegeneration and motor deficits [7–10]. It has been
shown in a PD-mouse model that administration of ceru-
loplasmin can attenuate neurodegeneration and thus, it
has been proposed that infusion of ceruloplasmin to PD
patients might be of therapeutic utility [7, 11].
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The loss of ceruloplasmin-ferroxidase activity observed
in PD patients might be the consequence of the protein
oxidation we observed [3] likely owing to redox changes
in pathological CSF [12, 13]. We also have previously
shown that ceruloplasmin oxidation may promote as-
paragine (Asn, N) deamidation, a spontaneous reaction
that occurs during protein aging and that leads to aspar-
tate (Asp, D) and isoaspartate (isoAsp, isoD) formation
[14]. In particular, two residues of ceruloplasmin (568N
and 962N), that are part of Asparagine-Glycine-Arginine-
(NGR)-sequences, can deamidate with a fast kinetics
[14] leading to the formation of isoDGR, a motif capable
of recognizing the Arginine-Glycin-AsparticAcid-(RGD)-
binding site of integrins [15, 16]. Accordingly, in vitro
NGR-deamidation in ceruloplasmin is associated with
gain of integrin-binding and intracellular signalling func-
tions, that through FAK1, ERK1/2, Akt and MAPK
involvement may regulate gene activation, cell cycle,
proliferation, and actin cytoskeleton rearrangement [14].
While 568N is exposed on the protein surface and can
rapidly deamidate in vitro, deamidation of 962N requires
protein oxidation and structural changes, being this resi-
due buried within the protein tertiary structure [14].
These notions prompted us to investigate whether the
loss of ferroxidase activity in PD patients is accompanied
by NGR-to-isoDGR transition. We show here that the
endogenous ceruloplasmin in the CSF of PD patients ex-
hibited structural changes, deamidation of the 962NGR-
motif and gain of integrin binding function, owing to the
presence of abnormal levels of hydrogen peroxide in the
CSF. Interestingly, the pathological environment in the
CSF of PD patients promotes the same modifications in
the exogenously added ceruloplasmin, with the conse-
quent loss of ferroxidase activity and gain of integrin bind-
ing properties, which in turn rise warnings about a
potential therapeutic use of ceruloplasmin in patients.
Results
The endogenous ceruloplasmin in the CSF of PD patients
exhibits structural changes, deamidation of the 962NGR-
motif and gain of integrin binding function
To investigate whether the oxidative modifications we
observed in the ceruloplasmin from the CSF of PD
patients [3] were also associated with structural
changes that may foster 962NGR- to isoDGR-motif
transition, as reported for ceruloplasmin in vitro [14],
we performed a limited trypsin proteolysis assay. The
endogenous ceruloplasmin in the CSF from PD pa-
tients showed higher sensitivity to proteolysis than
did that in the CSF from healthy subjects (Fig. 1a),
indicating the structural changes occur in the
patients' CSF. This finding suggested that deamidation
Fig. 1 Ceruloplasmin in PD patients CSF shows structural changes, 962NGR-motif deamidation and gain of integrin-binding function. a)
Structural changes. Western blot analysis after limited trypsin proteolysis (Try, +) showed higher sensitivity of the endogenous ceruloplasmin from PD’s
CSF compared to Cp from healthy subjects (H-CSF). b) Deamidationof the 962NGR-motif. CSF samples (70 μl each) from healthy subjects (H, n = 13) and
PD patients (PD, n = 10) were digested with trypsin and directly analysed by quantitative parallel reaction monitoring mass spectrometry.
Data are reported as peak-intensity of the peptide containing the 962NGR-motif as it is (MHAINGR) and deamidated (MHAIDGR), normalized
for the ceruloplasmin internal reference peptide (IRP), namely LISVDTEHSNIYLQNGPDR, which yielded the lowest median CV for both 962NGR- and
962DGR-containing peptides. Five technical replicates for each sample were run and use for the quantification. c) Binding to αvβ6 of endogenous
ceruloplasmin from CSF of healthy subjects (H-CSF) or PD patients (PD-CSF) revealed by ELISA at time zero or after 9 days aging. Two
independent experiments in triplicate were performed using CSFs of different subjects in each experiment (total subjects for each group
n = 8). In B and C data were analyzed by student’s t test; means with standard error, calculated using pooled data from different experiments,
are indicated (** = p < 0.01)
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of 962NGR-motifs may take place in vivo in the patients.
Quantitative mass spectrometry (MS) analysis per-
formed by parallel reaction monitoring (PRM) on the
CSF of healthy subject (H-CSF, n = 13) and PD pa-
tients (PD-CSF, n = 10) confirmed that the deamida-
tion of the endogenous ceruloplasmin 962NGR-motif
was significantly higher (p = 0.0094) in PD patients
compared to healthy subjects (Fig. 1b). On the
contrary to the 962NGR-motif, the 568NGR-motif was
poorly- or not-deamidated in both control and PD
patients (data not shown). No correlations have been
found between the rate of Cp-deamidation and the
demographic/clinical parameters evaluated in patients
(age, disease duration, disease score), nor correlation
has been found with the samples' time of storage at
−80 °C (not shown). Considering the physiological ce-
ruloplasmin concentration of about 1.5 μg/ml in the
CSF [17], the increased deamidation of about 18 %
found in PD-CSF compared to H-CSF (Fig. 1b), corre-
sponded to about 270 ng/ml of deamidated ceruloplasmin.
Furthermore, considering that the deamidated peptide
detected by mass spectrometry is representative of
both 962DGR and 962isoDGR forms, and that only the
latter is responsible for the integrin-binding, we can
hypothesize, according to the reported 50-75 % con-
version of NGR toward isoDGR [15], that the amount
of deamidated ceruloplasmin capable of integrin rec-
ognition ranges from 135 to 200 ng/ml. Therefore, we
then analysed the integrin-binding properties of the
endogenous ceruloplasmin. We tested the binding ac-
tivity to the αvβ6-integrin since we already reported
the specific binding capability of the in vitro oxi-
dized/deamidated ceruloplasmin to this integrin [14].
No specific binding to αvβ6-integrin was observed for
endogenous ceruloplasmin from both healthy subjects
and PD patients under resting conditions (Fig. 1c).
This finding was probably due to the lower sensitivity of
the ELISA compared to MS analysis, therefore, it is likely
that the scarcity of adhesive-ceruloplasmin (containing the
isoDGR) available determined the capture and detection
of this protein in very small amounts. Moreover, competi-
tion with other integrin-binding molecules present in CSF
(e.g. fibronectin, tenascin) was a further constraint on
adhesive-ceruloplasmin capture. Interestingly, if the CSFs
were aged in vitro for 9 days, a significant αvβ6-integrin
binding activity (p = 0.0023, CV <13 %) was induced ex-
clusively in the CSF from PD patients (Fig. 1c) suggesting
that the pathological environment can promote a gain-of-
integrin binding activity, likely mediated by 962NGR dea-
midation and isoDGR formation. These findings indicated
that ceruloplasmin deamidation of NGR-motifs occurs in
vivo in the patients CSF and suggested that the 962NGR-
motif plays a major role in the acquisition of the integrin
binding properties.
The CSF from PD patients promotes spiked ceruloplasmin
structural changes that foster loss of ferroxidase activity
and 962NGR-deamidation
In order to confirm that the environment of CSF from PD
patients can promote ceruloplasmin modifications, we
added purified ceruloplasmin to the CSF of healthy sub-
jects (H) or patients with peripheral neuropathies (PN) or
PD, and analysed it before and after incubation for differ-
ent times. Ceruloplasmin aged for 9 days in PD-CSF, but
not in H-CSF or PN-CSF, showed a higher sensitivity to
limited trypsin proteolysis and a significant reduction of
ferroxidase activity (p = 0.0011) (Fig. 2a and b). These
results indicated the occurrence of structural changes that
may be responsible for ceruloplasmin enzymatic activity
reduction as previously reported [3, 14, 18]. Semiquantita-
tive MS analysis of spiked ceruloplasmin-derived peptides
after incubation in PD-CSF was performed to characterize
the deamidation of NGR-sites. Similarly to what was
observed for the endogenous ceruloplasmin, the deamida-
tion of 962NGR, but not of 568NGR, was significantly
enhanced, compared to both controls H-CSF and PN-CSF,
after 9 days of incubation in PD-CSF (p = 0.0164) (Fig. 2c).
These findings support the hypothesis that structural
changes occur in ceruloplasmin after incubation in PD-
CSF, which are likely crucial for both loss of ferroxidase
activity and cryptic 962NGR/isoDGR-site exposure.
The CSF from PD patients promotes spiked ceruloplasmin
gain of integrin-binding function mediated by isoDGR-
motif/s
We analysed the ceruloplasmin integrin-binding proper-
ties before and after incubation in CSFs. Ceruloplasmin
aging in PD-CSF, but not in H-CSF or PN-CSF, could in-
duce αvβ6-integrin binding activity (p = 0.0091 and p =
0.0083 at 9 and 12 days, respectively) (Fig. 2d). The
binding was competed by an excess of isoDGR-peptide
(p = 0.0009), but not by a control ARA-peptide (Fig. 2e),
indicating that the environment of PD-CSF can promote
a gain-of-integrin binding activity, likely mediated by
962NGR deamidation and isoDGR formation.
Oxidative stress contributes to Cp-structural changes
To assess the contribute of oxidative stress in structural
and functional changes observed after ceruloplasmin
aging in PD-CSF, we analysed ceruloplasmin carbonyla-
tion before and after 9 days of incubation, as read-out of
protein oxidation promoted by reactive oxygen species.
Western blot (WB) analysis showed a weak carbonyla-
tion at time 0 in PN-CSF and PD-CSF, but not in H-CSF
(Fig. 3a). Remarkably, ceruloplasmin aging in PD-CSF,
but not in H-CSF or PN-CSF, induced an increase of
protein carbonylation (Fig. 3a), pointing to oxidative
stress in this condition.
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Interestingly, the PD-CSF showed a significant higher
concentration of hydrogen peroxide (48 μM) compared
to H-CSF or PN-CSF (p < 0.0001) (21.9 and 24.9 μM,
respectively) (Fig. 3b). This observation suggests a role
for hydrogen peroxide in ceruloplasmin oxidation and
consequent structural and functional changes. Accord-
ingly, degradation of hydrogen peroxide by catalase
addition at the beginning of incubation, prevented the
reduction of ceruloplasmin ferroxidase activity observed
after 9 days of incubation in PD-CSF (p < 0.0001) (Fig. 2b
and Fig. 3c). Noteworthy, the presence of catalase also
prevented the gain of integrin-binding activity of cerulo-
plasmin observed after 9 days of incubation in PD-CSF
(p = 0.009) (Fig. 3d). Of note, catalase could not reduce
the integrin-recognition of ceruloplasmin pre-oxidized/
deamidated in vitro (Cp-ox/AmBic) and added to H-CSF
(Fig. 3d), indicating that catalase was not able to revert
the oxidative modifications already induced, therefore
sustaining the evidence that catalase acts scavenging the
hydrogen peroxide present in PD-CSFs.
These findings support the hypothesis that hydrogen
peroxide was crucially involved in ceruloplasmin oxidation
Fig. 2 Incubation of ceruloplasmin spiked in the CSF of PD patients induces structural and functional modifications. Ceruloplasmin (Cp) was
added (20 μg/ml) to CSF from healthy subjects (H-CSF), peripheral neuropathies patients (PN-CSF) and PD patients (PD-CSF), and incubated for 0
or 9 days at 37 °C, then supplemented CSFs were directly used or ceruloplasmin was immunoprecipitated and used for different assays. a) Structural
changes. Immunoprecipitated samples were subjected to limited-trypsin digestion and analyzed by western blot with an anti-ceruloplasmin Ab (a
representative experiment is shown). b) Ferroxidase activity. The activity of immunoprecipitated Cp (1.25 μg) was evaluated by bathophenanthroline
assay and expressed as % of ferroxidase activity measured for 1.25 μg of untreated ceruloplasmin. Three independent experiments in triplicate were
performed using CSFs from different subjects in each experiment (total subjects for each group n = 8). C) Deamidation of NGR-motifs. Ceruloplasmin
immunoprecipitated from CFSs samples after 9 days of incubation, was trypsin-digested and analysed by mass spectrometry. Semi-quantitative
label-free evaluation was performed on the observed peptides containing either 568NGR- or 962NGR-motif as they are or deamidated. Data
are reported as ratio between deamidated and non-deamidated 568NGR or 962NGR quantitation; three independent experiments were performed
using CSF from different subjects each group (total subjects for each group n = 12; in PN-group the PN1 sample was used twice). d-e) Binding to
αvβ6-integrin of ceruloplasmin after different time of incubation (0–12 days at 37 °C) in different CSFs was evaluated by direct (d) or competitive (e)
αvβ6-integrin binding ELISA assay using the CSFs supplemented with ceruloplasmin. Competition experiments were performed using either
acetyl-CisoDGRCGVRSSSRTPSDKY (isoDGR) peptide or the control peptide acetyl-CARACGVRSSSRTPSDKY (ARA). Two independent experiments in
triplicate were performed using CSFs from different subjects in each experiment (total subjects for each group n = 8). In all assays data
were analyzed by student’s t test; means with standard error, calculated using pooled data from different experiments, are indicated
(*** = p < 0.001; ** = p < 0.01; * = p < 0.05)
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and in the induction of structural changes necessary for
loss of ferroxidase activity, 962NGR-deamidation and gain
of integrin-binding properties.
Discussion
In this study we demonstrated that, in addition to the
oxidative modifications and the loss of ferroxidase
activity already reported [3–7], the ceruloplasmin in the
CSF of PD patients undergoes to conformational
changes and NGR-motifs deamidation, which in turn
promote the gain of integrin-binding function. In vivo
NGR-deamidation, on the contrary to what was
observed in vitro [14], occurs primarily at the hidden
962NGR-site and not, or markedly less, on the surface-
exposed 568NGR. However, this finding is conceivable
because asparagine deamidation depends on neighboring
residues as well as on secondary and tertiary structure of
the protein, and is also affected by environmental factors
such as ionic strength and pH [19, 20]. The kinetic of
deamidation reactions is influenced by the combination
of these factors, thus can range from hours to years for
different residues under different conditions [19, 20]. As
962NGR-deamidation requires a conformational change
to occur [14], this implies that structural changes were
induced in PD-CSF ceruloplasmin, likely consequent to
the increased oxidation of CSF’s protein as reported in
PD [3, 21]. In vivo, asparagine deamidation has been
reported in pathological conditions associated with oxi-
dative stress as for example for Tau protein and β-
amyloid peptides in Alzheimer's disease [22–25]. Thus
the ceruloplasmin’s modification fostered by pathological
environment we described here might explain the loss of
Fig. 3 Oxidative stress contributes to ceruloplasmin structural changes and gain of integrin-binding function. a) Analysis of ceruloplasmin (Cp)
oxidation after incubation in H-CSF, PN-CSF, or PD-CSF. Cp was added to CSFs (20 μg/ml), incubated (37 °C) for 0 or 9 days, and immunoprecipitated.
One part of the product was analyzed for protein oxidation rate using the OxyBlot™ kit (based on anti-DNP WB analysis of protein carbonylation), and
the other part was analyzed by WB with anti-ceruloplasmin Ab. Two independent experiments were performed using pools of CSFs from 4 different
subjects per groups in each experiment (total subjects analyzed for each group n = 8) (a representative experiment is shown). b) Quantification of
hydrogen peroxide concentration in H-CSF (n = 16), PN-CSF (n = 11) and PD-CSF (n = 12) using the Amplex® Red Hydrogen Peroxide kit. c) Effect of
hydrogen peroxide depletion with catalase on the ceruloplasmin loss-of-ferroxidase activity induced by incubation in PD-CSF. Ceruloplasmin (20 μg/
ml) and catalase (60 μg/ml) were added to H-CSF or PD-CSF, left to incubate (37 °C) for 0 or 9 days, then the ferroxidase activity of immunoprecipitated
ceruloplasmin (1.25 μg) was evaluated by bathophenanthroline assay and expressed as % of ferroxidase activity measured for 1.25 μg of untreated
ceruloplasmin. d) Effect of catalase-mediated hydrogen peroxide depletion on the ceruloplasmin gain of integrin-binding properties induced
by incubation in PD-CSF. Ceruloplasmin and catalase were added to different CSFs as in C and analyzed by direct αvβ6-binding assay. To rule out a
non-specific effect of catalase on ceruloplasmin-integrin-binding, a control with ceruloplasmin pre-oxidized and deamidated in-vitro (Cp-ox/AmBic)
(right panel) was performed. In c and d, two independent experiments in triplicate were performed using CSFs from different subjects in each
experiment (total subjects for each group n = 8). In all experiments statistical p value was evaluated by student’s t test, means with standard
error, calculated using pooled data from different experiments, are indicated (**** = p < 0.0001 *** = p < 0.001, ** = p < 0.01)
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ceruloplasmin-ferroxidase activity reported in CSF and
substantia nigra of patients with PD [3–7]. This might
have relevant pathological implications in the brain cel-
lular iron homeostasis with consequent increase in iron
accumulation, oxidative damage and neurodegeneration.
We have previously shown that in vitro deamidation
of ceruloplasmin's NGR-motifs promotes the gain of
integrin-binding function, and that the interaction of
deamidate ceruloplasmin with integrins resulted in an
intracellular signal transduction that affects cell physi-
ology [3, 14]. The absence of binding to αvβ6-integrin
we found for endogenous ceruloplasmin from PD pa-
tients under resting conditions might depend on both,
the very low amount of deamidated ceruloplasmin suit-
able for the binding (namely the isoDGR isoform), and
the sensitivity of the method used for binding detection.
In addition, we also hypothesized that, in vivo, as soon
as the ceruloplasmin is modified, and thus becomes able
to bind the integrins, it is sequestered by the surround-
ing, integrin-expressing tissues. In fact, in vitro in the
absence of sequestering integrin-expressing tissue, the
CSF from PD patients aged for 9 days showed the acqui-
sition of the αvβ6-integrin binding activity. Interestingly
the gain of function was induced exclusively in the CSF
from PD patients and not in the control CSFs from
healthy subjects and PN patients. This rule out the in-
duction of methodological-artificial oxidative conditions
and suggested that the PD pathological environment was
able to promote a gain-of-integrin binding activity.
Whether the ceruloplasmin gain of integrin-binding
function observed in PD-CSF has favourable or detri-
mental effects on disease progression is difficult to pre-
dict at present and need further investigations. However,
since we reported that integrin binding by deamidated
ceruloplasmin is able to activate in vitro an intracellular
signaling cascades, which in turn could affect cell prolifer-
ation and cytoskeletal re-organization [14], it is conceiv-
able to hypothesize that the deamidated ceruloplasmin
found in PD patients might transduce unusual intracellu-
lar signals. Interestingly, an aberrant signaling mediated
via integrin engagement by fibrillar amyloid-β, which
resulted in neuronal dystrophy and death, has been
reported in Alzheimer's disease [26–28]. Several cell types
in the central nervous system might be potential targets of
deamidated ceruloplasmin, including microglial cells and
the specialized epithelial cells of the ependymal layer and
choroid plexus, the latter being directly in contact with
the CSF.
The second major finding of this work is that the CSF
of PD patients contains elements capable of promoting
structural and functional modifications in ceruloplasmin,
including, oxidation/carbonylation, loss of ferroxidase
activity, asparagine deamidation at the NGR-site and
acquisition of integrin-binding properties. Indeed, NGR-
deamidation of spiked ceruloplasmin was fostered ex vivo
in PD-CSF at higher rates than in normal-CSF and PN-
CSF used as control neurological disease. As for the en-
dogenous ceruloplasmin, the deamidation of spiked ce-
ruloplasmin occurs primarily at the hidden 962NGR-site,
which implies the requirement of conformational
changes as supported by the different sensitivity to lim-
ited proteolysis observed. These evidences suggest as a
logical consequence that PD-CSF contains compounds
capable of fostering these changes. Of note, we found
that the PD-CSF contains high levels of hydrogen perox-
ide, a highly reactive oxygen species, and that catalase,
an enzyme that converts hydrogen peroxide into water,
prevented both the inhibition of ferroxidase activity and
the acquisition of ceruloplasmin integrin-binding prop-
erties. Therefore, hydrogen peroxide known to be over-
produced in neurodegeneration [29], seems to be an
agent crucially involved in the structural and functional
modifications of ceruloplasmin in PD-CSF. Dealing with
metal ions, namely copper and iron, ceruloplasmin
results to be very susceptible to environment redox-
changes. However, in addition to the ceruloplasmin
prototype, several others proteins might be modified by
the pathological pro-oxidant environment in the CSF of
PD patients, as inferred by the greater level of total
protein carbonylation reported in the CSF of PD patients
[3, 21]. These oxidative modifications may have conse-
quences on proteins functions, like for example the
reported inhibition of the extracellular superoxide dismut-
ase enzymatic activity induced by the hydrogen peroxide
[30]. Interestingly, it has been reported a higher propensity
of α-synuclein (α-syn) to undergo deamidation, compared
to β-syn, a modification that favor the formation of stable
oligomers [31]. Thus, protein deamidation might foster
the α-syn aggregate formation in the CSF of PD patients,
where α-syn oligomers have been described [32–34]. Simi-
larly a deamidation-mediated protein aggregation it has
been reported for Tau and β-amyloid proteins in Alzhei-
mer’s disease [23–25]. The oligomers in the CSF might
contribute to the disease spreading according to the re-
cently proposed prion concept for aggregated proteins
both in Alzheimer’s and Parkinson’s diseases [35]. Further-
more, the high levels of hydrogen peroxide found in the
CSF of PD patients might have additional pathological im-
plications being this molecule able to affect several cellular
functions [36] (reviewed in [37]). Another important
question raised by the high level of hydrogen peroxide
observed in the PD-CSF is how this compound is
produced and/or accumulated in the CSF. An hypothesis
is that, the pathological features of PD like aberrant
autophagy and mitochondrial dis-functions that have been
reported to potentiate the production of hydrogen perox-
ide [38, 39], might be responsible for the observed
concentration increase.
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The faster kinetic of ceruloplasmin’s NGR-motifs dea-
midation and loss of ferroxidase activity observed during
ex vivo aging in PD-CSF compared to both H-CSF and
PN-CSF supports the hypothesis of a generally acceler-
ated protein aging in neurodegenerative diseases pro-
moted by the pathological environment [12, 13]. The
observation that approximately 50-60 % of the cerulo-
plasmin ferroxidase activity was lost after 9 days of aging
in the PD-CSF, and the fact that the ceruloplasmin con-
centration in the CSF is about 1.5 μg/ml with a physio-
logical half-life of about 5.5 days in vivo [1, 17], made
conceivable that ceruloplasmin modifications might
occur in patients to an extent that yields relevant con-
centration of non-functional protein, about 200 ng/ml
which is in line with the concentration rage also sug-
gested by PRM-MS results.
Our findings showing that the pathological CSF is able
to modify the ceruloplasmin arise warnings about a
potential therapeutic use of this protein in patients [7],
especially in the light of loss of ferroxidase activity pro-
moted by the PD-CSF environment. Despite the promis-
ing results obtained in murine models treated with
ceruloplasmin, it is presently unknown whether the CSF
of PD-mice can induce oxidative dysfunctions as ob-
served with human PD-CSF. Notably, in murine models
ceruloplasmin-activity’s reduction is associated with pro-
tein expression reduction, whereas in PD-patients the
activity reduction occurs in the presence of normal level
of ceruloplasmin-expression suggesting different mechan-
ism of ferroxidase activity impairment [7]. Furthermore,
the high conservation of the 568NGR- and 962NGR-motifs
across different species is not maintained in mouse and
rat; in these species the sequences are 568DGR- and
962NGK- respectively, the first not prone to isomerize to
isoDGR- and the second not described to be able to gener-
ate an integrin binding-motif when deamidated (Fig. 4).
Therefore, the risk exists that data obtained in animal
models might not completely predict the behaviour in PD
patients.
Conclusions
Our results show that, owing an aberrant hydrogen per-
oxide concentration, the pathological oxidative environ-
ment in PD-CSF is able to promote endogenous
ceruloplasmin loss-of-ferroxidase function and gain-of-
integrin binding activity. These effects might have im-
portant pathogenic implications affecting ceruloplasmin-
mediated iron homeostasis but also due to the potential
cell signaling triggered by the unusual ceruloplasmin
binding to integrin. Furthermore, there are pharmaco-
logical implications because the PD-CSF's pro-oxidant
properties raise the possibility that in human, the pro-
posed ceruloplasmin-based therapeutic approach might
not be efficacious.
Methods
Patients and CSF samples
CSF samples were obtained from the Institute of
Experimental Neurology-Biobank (San Raffaele Scientific
Institute) after approval from the hospital’s ethical com-
mittee and informed consent from patients. The analyzed
CFSs were from Parkinson’s disease patients (PD-CSF, n =
Fig. 4 Analysis of the conservation of the Cp’s NGR motifs across different species. Sequence alignment of NGR-motifs present in ceruloplasmin
from differing species was performed with ClustalX software (Conway Institute UCD, Dublin; www.clustal.org). The 568NGR- and 962NGR-motifs are
conserved along different species, however, in mouse and rat the conservation is not maintained
Barbariga et al. Molecular Neurodegeneration  (2015) 10:59 Page 7 of 12
12), peripheral neuropathies patients (PN-CSF, n = 11)
and healthy subjects (H-CSF, n = 16). All patients and
controls were at first diagnosis and drug-free. Patients
affected by probable idiopathic PD according to the
current diagnostic criteria [40] were clinically evaluated by
two expert neurologists and performed a thorough
clinical-instrumental evaluation, including magnetic res-
onance imaging, in order to disclose possible differential
diagnosis (i.e. vascular parkinsonism). The standard mag-
netic resonance imaging studies did not reveal region of
focal atrophy in the patients. None of the PD patients pre-
sented behavioural disorders, including hallucinations or
sleep disorders, at a thorough neurobehavioral and neuro-
psychological evaluation. Global cognitive efficiency was
within normal range (Mini Mental State Examination
≥27/30) for all PD subjects with the exception of PD12. At
the enrolment, all PD patients had short disease duration
(<1 year from symptoms onset) with the exception of
PD12. Motor system impairment and disease severity were
determined in PD patients’ group by means of Unified
Parkinson's Disease Rating Scale and Hoen and Yahr
Stage. A clinical-instrumental follow-up after 1 year from
the first hospitalization was done to confirm the diagnosis,
only patients with confirmed PD diagnosis were included
in the study and all presented a typical disease course.
A group of individuals affected by peripheral neuropa-
thies was used as control group of different neurological
disease. Current criteria for the diagnosis of PN were
used for admission into the study [41]. Evaluation for dis-
ability was done according to Appel procedure; all patients
underwent the normal procedure of differential diagnosis
including haematological examination, electroneurographic
and electromyographic evaluations, and CSF examin-
ation. At neurological examination all patients showed
neurogenic changes and no motor or sensory conduc-
tion abnormalities. The disease course was chronically
progressive in all cases. Patients were submitted to
neurological examination using strength evaluation
(MRC grading system) and Verbal-Numerical Pain Rat-
ing Scales performed at first hospitalisation and 6 and
12 months later, by the same neurologist.
Healthy CSFs were from subjects who underwent lum-
bar puncture on account of a suspected neurological
disease and who proved to be free from pathological
alterations after complete CSF analysis and clinic-
neuroimaging assessment. All controls reported negative
history of neurologic disorders and were normal on
neurological examination. Exclusion criteria for all
groups were: HIV/HCV-seropositivity; previous cere-
bral ischemic events; severe metabolic disorders. No
statistical differences among all groups were found for
sex distribution (Fischer’s exact test), for total protein
concentration (Student’s t-test), and for patients age (H
vs. PD and PD vs. PN groups comparison), whereas H
vs. PN showed a p = 0.0317 (Mann–Whitney test).
Demographic and clinical features of PD patients and
control groups are summarized in Table 1 and Table 2,
respectively.
CSF samples (2–3 ml) were collected for bio-banking
purposes by lumbar puncture and the first drops were
discarded to avoid the artificial blood contamination.
One ml of each CSF sample was made available for this
study (2.5 ml for H1, PD10 and PD11 subjects). We set
up a 40–50 min procedure for collection, processing and
Table 1 Demographic and clinical features of Parkinson’ disease patients
Sex Age at
examination




UPDRS I UPDRS II UPDRS III Hoen & Yahr MMSE
#1 M 65 0.38 PD 7 Tremble 0 4 4 1 30
#2 F 56 0.46 PD 10 Akinetic 1 9 29 1 29
#3 F 68 0.51 PD 8 Akinetic 2 3 14 2 28
#4 M 60 0.34 PD 10 Tremble 0 5 6 1.5 30
#5 M 70 0.39 PD 9 Tremble 0 3 5 1 30
#6 F 70 0.41 PD 12 Tremble 1 5 7 2 27
#7 F 73 0.46 PD 8 Tremble 3 9 19 1 29
#8 M 56 0.30 PD - Tremble 3 5 26 2 30
#9 F 66 0.60 PD 13 Tremble 0 8 17 1 30
#10 F 82 0.16 PD 9 Tremble 2 10 14 1 27
#11 M 80 0.47 PD - Akinetic 1 7 22 1.5 29
#12 F 56 0.19 PD + D >12 Akinetic 7 20 34 2.5 22
5 M/7 F 66.5 ± 8.3 0.39 ± 0.13
m ± sd m ± sd
[C] mg/ml = CSF total protein concentration; UPDRS = Unified Parkinson’s Disease Rating Scale; m =mean; sd = standard deviation
PD = Parkinson’s disease; D = dementia; Diag: confirmed diagnosis; MMSE: Mini Mental State Examination
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storage at −80 °C all CSF samples. Within this time
frame samples remained at room temperature for 15–
20 min for pneumatic tube transport, and at 4 °C for
further 20–35 min during which the samples were
centrifuged (800 x g, 10 min at 4 °C) to eliminate
cells; then samples, were either immediately used or
stored at −80 °C in a N2-supplemented atmosphere to
avoid the exposure to oxidative-environment. No dif-
ferences in results were observed in the different as-
says using fresh or stored CSF. For hydrogen
peroxide quantification, the samples have been used
within 6 months of storage and CSF aliquots were
used only once to avoid repeated thawing/freezing cy-
cles. CSF samples’ blood contamination was rule-out
in all samples as no hemoglobin was detected by both
WB and spectrophotometric analysis at 415 nm (see
Additional File 1: Figure S1 and Table S1). The pH of
the CSF from different groups was similar (H-CSF
pH 8.58 ± 0.14, PN-CSF, pH 8.42 ± 0.32; and PD-CSF,
pH 8.61 ± 0.12) and consistent with the reported
values for collected CSF [42]. The pH reached 9.65 ±
0.01 in all groups at the end of the ex vivo incubation
time (see below). Due to the limited amount of CSF
samples available, and depending on the sample’s vol-
ume necessary for the different assays, not all the pa-
tients and controls were used in each experiment;
numbers of subjects used in the different assays are
indicated in the figure legends.
Incubation treatments of ceruloplasmin in CSFs and
immunoprecipitation
Purified human ceruloplasmin (Alexis Biochemicals)
was added to CSFs (20 μg/ml, final concentration) and
incubated at 37 °C to the indicate time points under
nitrogen-conditioned atmosphere, to avoid the expos-
ure to atmospheric oxidative environment; in selected
experiments, incubation was performed in presence of
catalase (60 μg/ml, Sigma-Aldrich). After incubation in
CSFs, spiked ceruloplasmin was immunoprecipitated
using protein-G agarose beads (Invitrogen) coated with
polyclonal sheep anti-ceruloplasmin antibody (Ab)
(ab8813 Abcam, raised against full length purified cerulo-
plasmin) cross-linked with 20 mM dimethyl-pimelimidate
(Sigma-Aldrich). This polyclonal Ab anti-ceruloplasmin
was selected for its ability to equally immunoprecipi-
tate both resting- and oxidized-ceruloplasmin (see
Additional File 1: Figure S2). Ceruloplasmin was
eluted with 0.1 M glycine, pH 2.5, and diafiltered
(Amicon-Millipore) in PBS. In vitro oxidation and
deamidation of ceruloplasmin (Cp-ox/AmBic) was
achieved by incubation (16 h at 37 °C) in 100 mM
Table 2 Demographic and clinical features of control groups
H PN
Sex Age at examination [C] mg/ml Sex Age at examination [C] mg/ml Diagnosis
#1 F 70 0.34 F 50 0.23 pnp-infl
#2 M 72 0.32 F 60 0.35 pnp-infl
#3 M 76 0.36 F 69 0.75 pnp-infl
#4 F 43 0.21 M 46 0.45 pnp-idio
#5 M 54 0.25 M 75 0.26 pnp-infl
#6 M 72 0.27 M 50 0.58 pnp-infl
#7 M 46 0.47 M 80 0.41 pnp-idio
#8 F 62 0.34 F 39 0.41 pnp-infl
#9 M 78 0.53 M 31 0.77 pnp-infl
#10 F 59 0.35 M 35 0.51 pnp-tox
#11 M 81 0.47 F 64 0.32 pnp-tox
#12 M 76 0.52
#13 M 82 0.43
#14 F 69 0.28
#15 M 73 0.57
#16 F 78 0.77
10 M/6 F 68.2 ± 12 0.41 ± 0.15 6 M/5 F 54.5 ± 16.4 0.46 ± 0.18
m ± sd m ± sd m ± sd m ± sd
H = healthy subjects; PN = peripheral neuropathies; [C] mg/ml = CSF total protein concentration; m =mean; sd = standard deviation; pnp-infl = peripheral
neuropathy inflammatory; pnp-idio = pnp-idiopathic; pnp-tox = pnp-toxic
Barbariga et al. Molecular Neurodegeneration  (2015) 10:59 Page 9 of 12
ammonium bicarbonate buffer pH 8.5, containing
10 mM hydrogen peroxide [14].
Ceruloplasmin binding to αvβ6 integrin and competition
with isoDGR peptide
Recombinant αvβ6 integrin (R&D Systems, 1 μg/ml in
PBS-Ca2+/Mg2+) was added to 96-well plates and incu-
bated 16 h at 4 °C; subsequent steps were carried out at
20 °C. After blocking with 3 % BSA-PBS, the plates were
filled (50 μl/well 1:1 in binding buffer, 25 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1 mM MnCl2,
0,05 % Tween, 1 % BSA) with CSF samples either from
healthy or pathological subjects, or in selected experi-
ments with CSF samples previously supplemented with
ceruloplasmin or with Cp-ox/AmBic and incubated for
2 h. Binding was detected using the sheep polyclonal
anti-human ceruloplasmin Ab (ab8813, Abcam) followed
by a secondary HRP-conjugate Ab (Abcam) and by o-
phenylendiamine chromogenic substrate. Competitive
binding assays were performed by mixing 30 μg/ml of ei-
ther the acetyl-CisoDGRCGVRSSSRTPSDKY peptide
(isoDGR-peptide) or the control peptide CARACGVRS
SSRTPSDKY (ARA-peptide) [43] with CSF samples
spiked with ceruloplasmin.
Mass spectrometry analysis
Analysis on spiked-in ceruloplasmin
For MS analysis, we used a protocol set up as to
avoid experimental protein oxidation and/or deamida-
tion [14]. In brief, ceruloplasmin eluted from the im-
munoprecipitation was diafiltered in digestion buffer
(50 mM Na3PO4 pH 7.3, 150 mM NaCl, 25 mM
HEPES) and incubated with trypsin (0.1 μg/μl, Roche
Diagnostics) for 2 h at 20 °C. Samples were desalted
(Stage tips C18, Thermo Scientific) and injected in a
capillary chromatographic system (EasyLC, Proxeon
Biosystem). Peptide separations occurred on a 25 cm
reverse phase silica capillary column, packed with 3-
μm ReproSil-Pur 120 C18-AQ. A gradient of aceto-
nitrile eluents was used to achieve separation
(0.15 μL/min flow rate). MS analysis was performed
by nanoLC-MS/MS using an LTQ-Orbitrap (Thermo
Scientific) equipped with a nano-electrospray ion
source (Proxeon Biosystems). Full scan spectra were
acquired with the lock-mass option, resolution set to
60,000, and mass range from m/z 300 to 1750 Da.
The ten most intense doubly and triply charged ions
were selected and fragmented in the ion trap. All
MS/MS samples were analyzed using Mascot (v.2.2.07,
Matrix Science) search engine to search the Uni-
Prot_Human Complete Proteome_cp_hum_2013_12.
Searches were performed with 3-missed cleavages
allowed, N-terminus-acetylation, methionine oxidation
and deamidation of asparagine/glutamine as variable
modifications. Mass tolerance was set to 5 ppm and
0.6 Da for precursor and fragment ions, respectively.
To quantify deamidation the raw data were loaded
into the MaxQuant software v1.3.0.5. Label-free pro-
tein quantification was based on the intensities of
precursors. Peptides and proteins were accepted with
a FDR of 0.01, two minimum peptides per protein
with one unique peptide.
Analysis on endogenous ceruloplasmin
CSF samples (70 μl each) were diluted (1:2) with diges-
tion buffer and incubated 12 h at 20 °C in the presence
of trypsin 1:10 (w/w). The tryptic mixture was desalted
and injected in a capillary chromatographic system
(EASY-nLC™ 1000 Integrated Ultra High Pressure
Nano-HPLC System, Proxeon Biosystem) for peptide
separations on a 10 cm reverse phase silica capillary
column, packed with 1.9-μm ReproSil-Pur 120 C18-
AQ. A 60 min-gradient of acetonitrile was used to
achieve separation (0.30 μL/min flow rate). Parallel re-
action monitoring (PRM) analyses were performed using a
Q-Exactive mass spectrometer (Thermo Scientific). The
acquisition method combined two scan events corre-
sponding to a full scan MS (resolution set to 35,000 at m/
z 200) and a PRM event (resolution set to 17,500 at m/z
200; isolation window set to 2 m/z; maximum fill time of
120 ms and normalized collision energy set to 27) which
targeted the precursor ions of the peptides at their rele-
vant charge states in 1 min window. Using trypsin-
digested purified Cp and Cp-ox/AmBic, a local spectral
library was created to generate reference MS/MS spectra
(b- and y-fragment ions) and to determine the elution
time for each peptide. Data processing was performed
with Skyline software, freely available [44]. The quantifica-
tion was performed, post-acquisition, by extracting the
chromatographic traces of specific fragment ions, from 3
to 5 transitions. For each targeted peptide, extracted ion
chromatograms were selected for three to five transitions.
Peak areas, calculated from the sum of transitions (exclud-
ing the precursors), were automatically estimated by Sky-
line software. Internal reference peptides (IRPs) were
selected as unmodified proteotypic peptides with good sig-
nal stability and a wide range of elution times. The sum of
transition peak areas for each peptide was divided either by
the sum of transition peak areas for individual reference Cp
peptides or by the sum of the transition peak areas for all
reference Cp peptides [45]. The use of the Cp reference
peptide LISVDTEHSNIYLQNGPDR yielded the lowest me-
dian CV (10.7 %) for both 962NGR- and 962DGR-containing
peptides. Five technical replicates for each sample were run.
Western blot Ceruloplasmin immunoprecipitated
from CSF after incubation was resolved by 10 %-
acrylamide SDS-PAGE, and analyzed by WB as
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described in [3] with the polyclonal sheep anti-human
ceruloplasmin Ab (ab8813, Abcam) followed by a
secondary HRP-conjugate Ab (Abcam); images were
acquired using a laser densitometer (Molecular
Dynamics).
Bathophenanthroline assay Ferroxidase activity of
spiked ceruloplasmin after aging in CSF was evaluated
by bathophenanthroline (Btp) assay as described in
[3] on the immunoprecipitated ceruloplasmin. Briefly,
1.25 μg of immunoprecipitated ceruloplasmin was
incubated with 80 mM FeSO4 and analysed after 1 h
with a solution of 1 mM Btp in acetate buffer,
pH 6.2. Decrease in Btp-Fe2+ complex absorbance at
535 nm derives from ferrous iron oxidation into ferric
form (Fe3+). Ferroxidase activity was reported as
percentages of the activity recorded for 1.25 μg of un-
treated ceruloplasmin.
Ceruloplasmin sensitivity to limited proteolysis
Spiked ceruloplasmin after aging in CSF was immuno-
precipitated from CSF and 100 ng were resuspended in
25 μl of digestion buffer followed by incubation for 2 h
at 20 °C in the presence of agarose-immobilized trypsin
(0.5 U) (Sigma-Aldrich). Trypsin was removed by cen-
trifugation, and samples were analysed by SDS-PAGE
and WB.
Carbonylation assay The carbonylation level of cerulo-
plasmin immunopreciptated from CSF after aging, was
analyzed as in [3] with the OxyBlot Protein Oxidation
Detection Kit (Millipore Bioscience) on the basis of
carbonyl group derivatization with 2,4-dinitrophenil-
hydrazine (DNP). After derivatization with DNP, ceru-
loplasmin (300 ng) was resolved by SDS-PAGE, and
carbonyl groups were detected by WB using an anti-
DNP Ab.
Hydrogen peroxide assay Hydrogen peroxide concen-
tration in the CSFs was evaluated using the Hydrogen
Peroxide Assay Kit (BioVision) that is based on the
reaction between the H2O2 and a non-fluorescent
probe (AmplexRed®) that produces a fluorescent com-
pound. The analysis was performed on either freshly
collected CSF or samples stored at −80 °C for less
than 6 months and that were not previously thawed.
Samples were analyzed in triplicate diluting CSF 1:100
in the assay buffer according to the manufacturer
protocol, and H2O2 concentration was evaluated as
fluorescence at 590 nm.
Statistical Analysis Sex distribution was analyzed by
using Fisher’s exact test and two-tailed p value. Con-
tinuous data were evaluated by unpaired student’s t-
test, if the data passed the normality test for Gaussian
distribution as assessed by the Kolmogorov-Smirnov
test, or were evaluated by Mann Whitney test; two-
tailed p value was used for the comparison of two
means and standard error. In all analyses, p < 0.05
was considered to be statistically significant. The
analysis was performed with GraphPad Prism V5
software.
Additional files
Additional file 1: Figure S1. Western blot analysis for contaminant
hemoglobin detection. Figure S2. Immunoprecipitation of both resting-
and oxidized-ceruloplasmin.Table S1. Spectrophotometric analysis for
hemoglobin contaminant detection in CSF samples. (PDF 1445 kb)
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